Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)

​ Conditions: Focal Cortical Dysplasia; Tuberous Sclerosis Complex (TSC); Hemimegalencephaly

Interventions: Drug: SVG103

Sponsors: SoVarGen Co., Ltd.

Not yet recruiting Conditions: Focal Cortical Dysplasia; Tuberous Sclerosis Complex (TSC); Hemimegalencephaly
Interventions: Drug: SVG103
Sponsors: SoVarGen Co., Ltd.
Not yet recruiting